The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data-Reference-Cited by-同舟云学术

The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data

Published:2022-07-08 Issue:9 Volume:65 Page:1424-1435
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Zou Xiantong^ORCID,Huang Qi,Luo Yingying,Ren Qian,Han Xueyao,Zhou Xianghai^ORCID,Ji Linong^ORCID

Funder

Beijing Municipal Science and Technology Commission

National Natural Science Foundation of China

National Key R&D Program of China

Beijing Nova Program of Science and Technology

Beijing Nova Cross program

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00125-022-05748-9.pdf

Reference19 articles.

1. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744

2. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925

3. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

4. Chung WK, Erion K, Florez JC et al (2020) Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43(7):1617–1635. https://doi.org/10.2337/dci20-0022

5. Ahlqvist E, Storm P, Karajamaki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18)30051-2

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A second step towards precision medicine in diabetes;Nature Metabolism;2024-01-23

2. Precision medicine in diabetes - current trends and future directions. Is the future now?;Comprehensive Precision Medicine;2024

3. An up-to-date systematic review on machine learning approaches for predicting treatment response in diabetes;Internet of Things and Machine Learning for Type I and Type II Diabetes;2024

4. Personalized glucose-lowering effect of chiglitazar in type 2 diabetes;iScience;2023-11

5. Machine learning in precision diabetes care and cardiovascular risk prediction;Cardiovascular Diabetology;2023-09-25